ABLYNX WILL ANNOUNCE ITS FULL YEAR RESULTS 2014 WITH WEBCAST
February 19, 2015 01:06 ET
|
Ablynx
GHENT, Belgium, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] will announce its full year results for 2014 on Thursday 26 February 2015 at 7.00 am CET.
The Ablynx management...
ABLYNX SUCCESSFULLY OPPOSES PATENT APPEAL CASE BY DOMANTIS (GSK)
January 22, 2015 01:04 ET
|
Ablynx
GHENT, Belgium, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it has been successful in opposing the appeal lodged by Domantis (now a member of the...
ABLYNX ANNOUNCES WARRANT EXERCISE
January 21, 2015 01:05 ET
|
Ablynx
GHENT, Belgium, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that...
ABLYNX TO PRESENT AT THE 33rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
January 07, 2015 01:09 ET
|
Ablynx
GHENT, Belgium, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that its CEO, Dr Edwin Moses, will present at the 33rd Annual J.P. Morgan Healthcare Conference on...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
December 24, 2014 01:05 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Dec. 24, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX], today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007...
ABLYNX OPENS RECRUITMENT FOR FIRST-IN-INFANT PHASE IIa STUDY WITH ITS ANTI-RSV NANOBODY, ALX-0171
December 17, 2014 01:09 ET
|
Ablynx
ALX-0171 is a first-in-class anti-RSV Nanobody® administered via inhalation
ALX-0171 was well tolerated in multiple Phase I clinical studies in adults
ALX-0171 has demonstrated a...
ADDITIONAL CLINICAL DATA FROM THE PHASE II STUDY WITH ABLYNX'S ANTI-vWF NANOBODY, CAPLACIZUMAB, PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
December 08, 2014 10:06 ET
|
Ablynx
Caplacizumab is a potential first-in-class therapeutic with Orphan Drug status
Caplacizumab, in addition to plasma exchange and immunosuppressive therapy, has the potential to become an...
ABLYNX DEMONSTRATES BIOEQUIVALENCE BETWEEN LIQUID AND LYOPHILISED FORMULATIONS OF ITS ANTI-vWF NANOBODY, CAPLACIZUMAB
November 26, 2014 01:06 ET
|
Ablynx
Caplacizumab has first-in-class potential for the treatment of thrombotic thrombocytopenic purpura (TTP)
On track to start Phase III study in patients with acquired TTP in mid-2015
GHENT,...
ABLYNX APPOINTS JOHAN HEYLEN AS CHIEF COMMERCIAL OFFICER
November 18, 2014 01:06 ET
|
Ablynx
GHENT, Belgium, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced the appointment of Johan Heylen as Chief Commercial Officer. Mr Heylen will assume responsibility for...
ABLYNX TO PRESENT AT THE JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE IN LONDON
November 17, 2014 01:04 ET
|
Ablynx
GHENT, Belgium, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it will present at the Jefferies 2014 Global Healthcare Conference at the Waldorf Hilton in...